Cargando…
Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients
Background: Chemotherapy is a cornerstone of treatment in advanced gastric cancer (GC) with a proven impact on overall survival, however, reliable predictive markers are missing. The role of various inflammatory markers has been tested in gastric cancer patients, but there is still no general consen...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432226/ https://www.ncbi.nlm.nih.gov/pubmed/34501353 http://dx.doi.org/10.3390/jcm10173902 |
_version_ | 1783751115466080256 |
---|---|
author | Konopka, Kamil Micek, Agnieszka Ochenduszko, Sebastian Streb, Joanna Potocki, Paweł Kwinta, Łukasz Wysocki, Piotr J. |
author_facet | Konopka, Kamil Micek, Agnieszka Ochenduszko, Sebastian Streb, Joanna Potocki, Paweł Kwinta, Łukasz Wysocki, Piotr J. |
author_sort | Konopka, Kamil |
collection | PubMed |
description | Background: Chemotherapy is a cornerstone of treatment in advanced gastric cancer (GC) with a proven impact on overall survival, however, reliable predictive markers are missing. The role of various inflammatory markers has been tested in gastric cancer patients, but there is still no general consensus on their true clinical applicability. High neutrophil-to-lymphocyte (NLR) and low (medium)-platelets-volume-to-platelet ratio (PVPR) are known markers of unspecific immune system activation, correlating significantly with outcomes in advanced GC patients. Methods: Metastatic GC patients (N:155) treated with chemotherapy +/− trastuzumab were enrolled in this retrospective study. Pre-treatment NLR and PVPR, as well as other inflammatory markers were measured in peripheral blood. Univariate Cox regression was conducted to find markers with a significant impact on overall survival (OS) and progression-free survival (PFS). Spearman correlation and Cohen’s kappa was used to analyze multicollinearity. Multiple multivariable Cox regression models were built to study the combined impact of NLR and PVPR, as well as other known prognostic factors on OS. Results: Elevated NLR was significantly associated with increased risk of death (HR = 1.95; 95% CI: 1.17–3.24), and lower PVPR was significantly associated with improved outcomes (HR = 0.53; 95% CI: 0.32–0.90). A novel inflammatory marker, based on a combination of NLR and PVPR, allows for the classification of GC patients into three prognostic groups, characterized by median OS of 8.4 months (95% CI 5.8–11.1), 10.5 months (95% CI 8.8–12.1), and 15.9 months (95% CI 13.5–18.3). Conclusion: The NLR and PVPR score (elevated NLR and decreased PVPR) is a marker of detrimental outcome of advanced GC patients treated with chemotherapy. |
format | Online Article Text |
id | pubmed-8432226 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84322262021-09-11 Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients Konopka, Kamil Micek, Agnieszka Ochenduszko, Sebastian Streb, Joanna Potocki, Paweł Kwinta, Łukasz Wysocki, Piotr J. J Clin Med Article Background: Chemotherapy is a cornerstone of treatment in advanced gastric cancer (GC) with a proven impact on overall survival, however, reliable predictive markers are missing. The role of various inflammatory markers has been tested in gastric cancer patients, but there is still no general consensus on their true clinical applicability. High neutrophil-to-lymphocyte (NLR) and low (medium)-platelets-volume-to-platelet ratio (PVPR) are known markers of unspecific immune system activation, correlating significantly with outcomes in advanced GC patients. Methods: Metastatic GC patients (N:155) treated with chemotherapy +/− trastuzumab were enrolled in this retrospective study. Pre-treatment NLR and PVPR, as well as other inflammatory markers were measured in peripheral blood. Univariate Cox regression was conducted to find markers with a significant impact on overall survival (OS) and progression-free survival (PFS). Spearman correlation and Cohen’s kappa was used to analyze multicollinearity. Multiple multivariable Cox regression models were built to study the combined impact of NLR and PVPR, as well as other known prognostic factors on OS. Results: Elevated NLR was significantly associated with increased risk of death (HR = 1.95; 95% CI: 1.17–3.24), and lower PVPR was significantly associated with improved outcomes (HR = 0.53; 95% CI: 0.32–0.90). A novel inflammatory marker, based on a combination of NLR and PVPR, allows for the classification of GC patients into three prognostic groups, characterized by median OS of 8.4 months (95% CI 5.8–11.1), 10.5 months (95% CI 8.8–12.1), and 15.9 months (95% CI 13.5–18.3). Conclusion: The NLR and PVPR score (elevated NLR and decreased PVPR) is a marker of detrimental outcome of advanced GC patients treated with chemotherapy. MDPI 2021-08-30 /pmc/articles/PMC8432226/ /pubmed/34501353 http://dx.doi.org/10.3390/jcm10173902 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Konopka, Kamil Micek, Agnieszka Ochenduszko, Sebastian Streb, Joanna Potocki, Paweł Kwinta, Łukasz Wysocki, Piotr J. Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients |
title | Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients |
title_full | Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients |
title_fullStr | Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients |
title_full_unstemmed | Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients |
title_short | Combined Neutrophil-to-Lymphocyte and Platelet-Volume-to-Platelet Ratio (NLR and PVPR Score) Represents a Novel Prognostic Factor in Advanced Gastric Cancer Patients |
title_sort | combined neutrophil-to-lymphocyte and platelet-volume-to-platelet ratio (nlr and pvpr score) represents a novel prognostic factor in advanced gastric cancer patients |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8432226/ https://www.ncbi.nlm.nih.gov/pubmed/34501353 http://dx.doi.org/10.3390/jcm10173902 |
work_keys_str_mv | AT konopkakamil combinedneutrophiltolymphocyteandplateletvolumetoplateletrationlrandpvprscorerepresentsanovelprognosticfactorinadvancedgastriccancerpatients AT micekagnieszka combinedneutrophiltolymphocyteandplateletvolumetoplateletrationlrandpvprscorerepresentsanovelprognosticfactorinadvancedgastriccancerpatients AT ochenduszkosebastian combinedneutrophiltolymphocyteandplateletvolumetoplateletrationlrandpvprscorerepresentsanovelprognosticfactorinadvancedgastriccancerpatients AT strebjoanna combinedneutrophiltolymphocyteandplateletvolumetoplateletrationlrandpvprscorerepresentsanovelprognosticfactorinadvancedgastriccancerpatients AT potockipaweł combinedneutrophiltolymphocyteandplateletvolumetoplateletrationlrandpvprscorerepresentsanovelprognosticfactorinadvancedgastriccancerpatients AT kwintałukasz combinedneutrophiltolymphocyteandplateletvolumetoplateletrationlrandpvprscorerepresentsanovelprognosticfactorinadvancedgastriccancerpatients AT wysockipiotrj combinedneutrophiltolymphocyteandplateletvolumetoplateletrationlrandpvprscorerepresentsanovelprognosticfactorinadvancedgastriccancerpatients |